While the review has yet to come up with recommendations for financing the development of new drugs, it seems clear to me that it is well within the capacity of the pharmaceutical industry to contribute. A common argument made by drug companies is that they need to be guaranteed a reward if they are to invest in developing medicines that are unlikely to deliver the kind of returns that other investments may provide.
抗耐药性评估没有提出新药开发融资的建议，但对我来说，显然这在制药业的能力范围内。制药公司的一个共同观点是，如果要投资开发不可能带来其他投资可提供的回报的药物，就必须获得担保。该观点还认为，担保药物开发的唯一办法是允许提高价格直到需求匹配供给。